Therapeutic antibodies targeting such cell surface receptors (e.g., PD-1, CTLA4) have shown remarkable success in the treatment of some malignancies, and have proven that the blockage of so-called immune checkpoints is feasible for cancer therapy [6,7,8]. The gene discussed is PDCD1; the disease is cancer.